Articles tagged "Highly-sensitized"

2018 American Transplant Congress
Follow Up of Patients Treated with the IgG Endopeptidase (IdeS) for Desensitization and HLA Incompatible (HLAi) Kidney Transplantation
S. Jordan,¹ J. Choi,¹ E. Huang,¹ R. Najjar,¹ A. Peng,¹ X. Zhang,¹ S. Louie,¹ M. Haas,² S. Sethi,¹ I. Kim,¹ A. Vo.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction:Donor-specific antibodies (DSAs) create an immunologic barrier to transplantation. This prevents transplantation for a significant percentage of highly-HLA sensitized patients (HS). Current desensitization therapies are…
2018 American Transplant Congress
Molecular Monitoring for Kidney Allograft Injury Following HLA Incompatible Transplantation
A. Jackson,¹ B. Iglehart,¹ S. Bagnasco,³ N. Desai.²
¹Medicine, Johns Hopkins University, Baltimore, MD; ²Surgery, Johns Hopkins University, Baltimore, MD; ³Pathology, Johns Hopkins University, Baltimore, MD.
Elevated donor derived cell free DNA (ddcfDNA) has been shown to correlate with allograft rejection following heart, lung, and kidney transplantation. We investigated whether sequential…
2018 American Transplant Congress
Impact of De Novo DSA (DnDSA) on Outcomes in HLA-Sensitized (HS) Patients Transplanted after IVIG + Rituximab Desensitization (DES)
A. Vo,¹ O. Aubert,² H. Edmund,¹ A. Peng,¹ R. Najjar,¹ S. Supreet,¹ J. Choi,¹ K. Lim,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²Paris Translational Research Center for Organ Transplantation, Necker Hospital, Paris, France.
Introduction: Highly-HLA sensitized patients (HS) with donor specific antibodies (DSA) at transplant are at risk for Type 1 ABMR. However, the incidence of Type 2…
2018 American Transplant Congress
The Clinical Significance of Pretransplant C1q Assay Status in Positive Crossmatch Kidney Transplantation
J. Lee,¹ D. Kim,¹ B. Park,² S. Song,³ J. Lee,⁴ Y. Jung,¹ J. Lee,¹ J. Lee,¹ B. Kim,⁵ M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea; ²Laboratory Medicine, Asan MEdical Center, Seoul, Korea; ³Surgery, Ewha Womans University, School of Medicine, Seoul, Korea; ⁴Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea; ⁵Internal Medicine (Nephrology), Yonsei University College of Medicine, Seoul, Korea.
Background: Patients with a pretransplant donor-specific antibodies (DSA) are at higher risk for antibody-mediated rejection (AMR). However, not all DSA have the same pathogenetic potential.…
2018 American Transplant Congress
Non Active Desensitization Protocol: Improving Access to Kidney Transplant for Hyperimmunized Patients
S. Le Bot,¹ F. Delbos,² C. Garandeau,¹ S. Malard Castagnet,² A. Cesbron,² M. Hourmant.¹
¹Nephrology and Transplantation, CHU Hôtel Dieu, Nantes, France; ²Laboratoire HLA, Etablissement Français du Sang, Nantes, France.
Hyperimmunized patients have a bad access to renal transplantation, despite national priority programs and active desensitization protocols. After having noticed that some HLA antibodies decreased…
2018 American Transplant Congress
Immuoadsorption-Based Desensitization in Highly Sensitized Patients Awaiting Deceased Donor Kidney Transplantation.
C. Bureau, P. Galichon, Y. Luque, N. Ouali, E. Rondeau, C. Rafat.
Urgences Néphrologiques et Transplantation Rénale, Tenon Hospital, APHP, Paris, France.
An estimated 30% of patients on the waiting list are deemed highly sensitized due to preexisting anti-HLA antibodies often irrevocably precluding kidney transplantation (KT). Immunoadsorption…
2017 American Transplant Congress
Outcome of Living-Donor Kidney Transplantation in Cross-Match-Positive Recipients at a Single Center.
D. Okada,¹ M. Okumi,¹ K. Unagami,² T. Shimizu,¹ H. Ishida,¹ K. Tanabe.¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan; ²Nephrology, Tokyo Women's Medical University, Tokyo, Japan
BackgroundLiving-donor kidney transplantation in cross-match (XM)-positive patients remains high-risk and requires an optimal desensitization protocol. We started a desensitization protocol for XM-positive patients in January…
2017 American Transplant Congress
Does HLA Class of Complement Activating Donor Specific Antibodies Matter: Single Centre Retrospective Analysis of Renal Allograft Outcomes.
A. Babu,^1,2,3 D. Briggs,³ D. Mitchell,¹ N. Krishnan,² R. Higgins,¹ S. Daga.^1,2,4
¹Warwick Medical School, University of Warwick, Coventry, United Kingdom; ²Nephrology and Transplantation, University Hospitals Coventrya and Warwickshire, Coventry, United Kingdom; ³Histocompatibility and Immunogenetics, NHS Blood and Transfusion, Birmingham, United Kingdom; ⁴Nephrology and Transplantation, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Introduction. Complement activating donor specific antibodies may be associated with worse outcomes in a cohort of patients who have undergone HLA-AIT. We looked for differences…
2017 American Transplant Congress
Impact of Serum EDTA Treatment on Identification of Unacceptable Antigens for Kidney Transplant Candidates.
J. Xin, N. Brown, R. Upchurch, J. Weidner, S. Marino.
Pathology, University of Chicago Medicine, Chicago, IL
BACKGROUND AND AIMS: The prozone effect is one factor causing false negative reactions in HLA antibody testing. EDTA, which is commonly used to remove this…
2017 American Transplant Congress
Effective Targeting Plasma Cells with Daratumumab (Anti-CD38) and Mozobil (Anti-CXCR4) in a Sensitized Non-Human Primate Model.
J. Kwun,¹ B. Ezekian,¹ M. Manook,¹ E. Branum,¹ V. Curfman,¹ J. Park,^1,2 K. Freishlag,¹ J. Yoon,¹ S. Knechtle.¹
¹Surgery, Duke Transplant Center, Durham, NC; ²Surgery, Samsung Medical Center, Seoul, Korea
[Introduction] The presence of donor-specific antibodies (DSA) leads to antibody-mediated rejection (AMR) and decreased graft survival. Therefore efforts continue to be made to reduce DSA…

« Previous Page
1
…
7
8
9
10
11
…
15
Next Page »